<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343329</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00043058</org_study_id>
    <nct_id>NCT01343329</nct_id>
  </id_info>
  <brief_title>Controlling Hyperadrenergic Activity in Neurologic Injury</brief_title>
  <acronym>CHAIN</acronym>
  <official_title>Controlling Hyperadrenergic Activity in Neurologic Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is frequently associated with a hyperadrenergic state
      accompanied by elevated levels of plasma catecholamines. In its more severe presentation, the
      hyperadrenergic state presents as dysautonomia, which is characterized by paroxysmal
      alteration in vital signs, including tachycardia. The investigators hypothesize that
      intravenous (IV) esmolol is as effective at controlling heart rate in hyperadrenergic states
      as oral propranolol, which is the standard of care. Our primary endpoint is efficacy of IV
      esmolol vs a PRN regimen of intermittent B-blockade in controlling heart rate below a
      pre-specified level (&lt; 100 bpm) after Traumatic Brain Injury (TBI) or hemorrhagic neurologic
      injury. Heart rates will be recorded continuously as well as hourly.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to enroll subjects that fit study criteria.
  </why_stopped>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">February 14, 2014</completion_date>
  <primary_completion_date type="Actual">February 14, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Controlling heart rate in traumatic brain injured patients</measure>
    <time_frame>72 hrs</time_frame>
    <description>Once the patient is randomized and start getting the study medication, we monitor heart rate and other vital signs for 72hrs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Dysautonomia</condition>
  <arm_group>
    <arm_group_label>Subjects Receiving Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.</description>
    <arm_group_label>Subjects Receiving Esmolol</arm_group_label>
    <other_name>Brevibloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)</description>
    <arm_group_label>Subjects receiving Propranolol</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TBI (Moderate/Severe TBI (GCS 12 or Head AIS&gt;1) or hemorrhagic neurologic injury

          -  Hyperadrenergic Activity: At least one paroxysmal episode (lasting at least 15
             minutes) of Heart Rate 110 beats per minute during two or more consecutive days plus
             at least two more of the following that may not be better explained by another disease
             process (ex: sepsis):

        Temperature of 38.5C Respiratory Rate 20 breaths per minute Agitation Diaphoresis Dystonia
        Stimulus responsive (&quot;triggering of paroxysm&quot;)

        - Informed Consent obtained

        Exclusion Criteria:

          -  Patients that do not meet criteria for dysautonomia (as stated above)

          -  Age &lt;18 years

          -  Pregnancy

          -  Hypotension - requiring pressor therapy to maintain baseline adequate CPP or mean
             arterial pressure

          -  Cardiac arrhythmia - sinus bradycardia (HR &lt;60), 2nd or 3rd degree AV block

          -  Hemodynamic contraindications to intravenous beta-blockade such as a documented
             history of congestive heart failure (CHF), dependency on cardiac inotropes or
             documented bronchospastic disease

          -  Any patient on chronic beta blockade as an outpatient.

          -  Life expectancy &lt; 48 hours or patients with &quot;do not resuscitate orders&quot;

          -  Ongoing seizure activity

          -  Informed consent not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Ziai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/</url>
    <description>Main website for Johns Hopkins Hospital</description>
  </link>
  <reference>
    <citation>Hörtnagl H, Hammerle AF, Hackl JM, Brücke T, Rumpl E, Hörtnagl H. The activity of the sympathetic nervous system following severe head injury. Intensive Care Med. 1980 May;6(3):169--7.</citation>
    <PMID>7391345</PMID>
  </reference>
  <reference>
    <citation>Baguley IJ. Autonomic complications following central nervous system injury. Semin Neurol. 2008 Nov;28(5):716-25. doi: 10.1055/s-0028-1105971. Epub 2008 Dec 29. Review.</citation>
    <PMID>19115177</PMID>
  </reference>
  <reference>
    <citation>Fernández-Ortega JF, Prieto-Palomino MA, Muñoz-López A, Lebron-Gallardo M, Cabrera-Ortiz H, Quesada-García G. Prognostic influence and computed tomography findings in dysautonomic crises after traumatic brain injury. J Trauma. 2006 Nov;61(5):1129-33.</citation>
    <PMID>17099518</PMID>
  </reference>
  <reference>
    <citation>Cotton BA, Snodgrass KB, Fleming SB, Carpenter RO, Kemp CD, Arbogast PG, Morris JA Jr. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma. 2007 Jan;62(1):26-33; discussion 33-5.</citation>
    <PMID>17215730</PMID>
  </reference>
  <reference>
    <citation>Baguley IJ, Heriseanu RE, Felmingham KL, Cameron ID. Dysautonomia and heart rate variability following severe traumatic brain injury. Brain Inj. 2006 Apr;20(4):437-44.</citation>
    <PMID>16716989</PMID>
  </reference>
  <reference>
    <citation>Meythaler JM, Stinson AM 3rd. Fever of central origin in traumatic brain injury controlled with propranolol. Arch Phys Med Rehabil. 1994 Jul;75(7):816-8.</citation>
    <PMID>8024432</PMID>
  </reference>
  <reference>
    <citation>Chioléro RL, Breitenstein E, Thorin D, Christin L, de Tribolet N, Freeman J, Jéquier E, Schutz Y. Effects of propranolol on resting metabolic rate after severe head injury. Crit Care Med. 1989 Apr;17(4):328-34.</citation>
    <PMID>2702842</PMID>
  </reference>
  <reference>
    <citation>Pranzatelli MR, Pavlakis SG, Gould RJ, De Vivo DC. Hypothalamic-midbrain dysregulation syndrome: hypertension, hyperthermia, hyperventilation, and decerebration. J Child Neurol. 1991 Apr;6(2):115-22.</citation>
    <PMID>2045626</PMID>
  </reference>
  <reference>
    <citation>Silver JK, Lux WE. Early onset dystonia following traumatic brain injury. Arch Phys Med Rehabil. 1994 Aug;75(8):885-8.</citation>
    <PMID>8053795</PMID>
  </reference>
  <reference>
    <citation>Cuny E, Richer E, Castel JP. Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal Baclofen therapy. Brain Inj. 2001 Oct;15(10):917-25.</citation>
    <PMID>11595088</PMID>
  </reference>
  <reference>
    <citation>Chen JM, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007185. doi: 10.1002/14651858.CD007185.pub2. Review.</citation>
    <PMID>20091622</PMID>
  </reference>
  <reference>
    <citation>Harwood TN, Butterworth J, Prielipp RC, Royster RL, Hansen K, Plonk G, Dean R. The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery. J Cardiothorac Vasc Anesth. 1999 Oct;13(5):555-61.</citation>
    <PMID>10527224</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Wendy Ziai</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Dysautonomia</keyword>
  <keyword>Brain Injury</keyword>
  <keyword>Sympathetic hyperactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

